| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Background: Thromboxane B-2 (TxB(2)) and particularly 11-dehydrothromboxane B-2 (11-dTXB(2)) are widely Used as prognostic risk markers of platelet activation in cardiovascular diseases. The main errors in TxB(2) and 11-dTxB(2) determination include either low concentrations of circulating TxB(2) (1 - 2 pg/mL) and 11-dTxB(2) (0.9 - 4.3 pg/mL) or rather high transiency (mean TxB(2) half-life is approximately 5 minutes) as well as an incorrect pre-analytical phase set up. The aim of this study was to investigate the impact of a widely used purification step on the results of enzyme immunosorbent assay (EIA) - based measurement of the two selected thromboxanes. Methods: For the purpose of this study, 20 plasma samples (10 healthy donors, 10 patients under treatment with acetylsalicylic acid) were screened for TxB(2) and 11-dTxB(2) concentrations using commercial competitive EIA kits (Cayman Chemicals (TM), Tallinn, Estonia; Neogen (TM), Lexington, KY, USA) with or without the introduction of the purification procedure. Results: The purification step does not significantly affect the results of EIA measurements of the two of TxA(2) metabolites (TxB(2), 11-dTxB(2)) in human plasma. The levels of TxB(2) and 11-dTxB(2) determined in the plasma samples were not significantly changed (p<0.05) when the purification step was omitted compared to the purified samples. Conclusions: This study establishes a protocol allowing for reliable and reproducible plasma TxB(2) and 11-dTxB(2) EIA measurement for routine basic screening of platelet function. (Clin. Lab. 2012;58:177-183)
- Background: Thromboxane B-2 (TxB(2)) and particularly 11-dehydrothromboxane B-2 (11-dTXB(2)) are widely Used as prognostic risk markers of platelet activation in cardiovascular diseases. The main errors in TxB(2) and 11-dTxB(2) determination include either low concentrations of circulating TxB(2) (1 - 2 pg/mL) and 11-dTxB(2) (0.9 - 4.3 pg/mL) or rather high transiency (mean TxB(2) half-life is approximately 5 minutes) as well as an incorrect pre-analytical phase set up. The aim of this study was to investigate the impact of a widely used purification step on the results of enzyme immunosorbent assay (EIA) - based measurement of the two selected thromboxanes. Methods: For the purpose of this study, 20 plasma samples (10 healthy donors, 10 patients under treatment with acetylsalicylic acid) were screened for TxB(2) and 11-dTxB(2) concentrations using commercial competitive EIA kits (Cayman Chemicals (TM), Tallinn, Estonia; Neogen (TM), Lexington, KY, USA) with or without the introduction of the purification procedure. Results: The purification step does not significantly affect the results of EIA measurements of the two of TxA(2) metabolites (TxB(2), 11-dTxB(2)) in human plasma. The levels of TxB(2) and 11-dTxB(2) determined in the plasma samples were not significantly changed (p<0.05) when the purification step was omitted compared to the purified samples. Conclusions: This study establishes a protocol allowing for reliable and reproducible plasma TxB(2) and 11-dTxB(2) EIA measurement for routine basic screening of platelet function. (Clin. Lab. 2012;58:177-183) (en)
|
| Title
| - The Purification Step is not Crucial in EIA Measurements of Thromboxane B-2 and 11-Dehydrothromboxane B-2 in Human Plasma
- The Purification Step is not Crucial in EIA Measurements of Thromboxane B-2 and 11-Dehydrothromboxane B-2 in Human Plasma (en)
|
| skos:prefLabel
| - The Purification Step is not Crucial in EIA Measurements of Thromboxane B-2 and 11-Dehydrothromboxane B-2 in Human Plasma
- The Purification Step is not Crucial in EIA Measurements of Thromboxane B-2 and 11-Dehydrothromboxane B-2 in Human Plasma (en)
|
| skos:notation
| - RIV/00064190:_____/12:#0000312!RIV13-MZ0-00064190
|
| http://linked.open...avai/predkladatel
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00064190:_____/12:#0000312
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - Plasma; thromboxane B-2; 11-dehydrothromboxane B-2; enzyme immunosorbent assay; purification; platelets (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - DE - Spolková republika Německo
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Paluch, Zoltán
- Alušík, Štefan
- Sadílková, Lenka
- Mottlová, Jiřina
|
| http://linked.open...ain/vavai/riv/wos
| |
| issn
| |
| number of pages
| |
| is http://linked.open...avai/riv/vysledek
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)